Ultimovacs AS operates as a pharmaceutical company. The firm engages in the development of novel immunotherapies against cancer. Its product, UV1, is a therapeutic cancer vaccine that activates the immune system to recognize telomerase. The company was founded on January 26, 2011 and is headquartered in Oslo, Norway.
Oslo, January 6, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors,...
Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business...
Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy...
